Cowles spoke with ScienceBoard.net at the 2022 Biotechnology Innovation Organization (BIO) International Convention about EpiCypher's efforts to harness the power of chromatin science and provide insights into the chromatin regulatory system, which plays a critical role in many disease processes.

"What we do is we study and provide tools to let researchers get the regulation information off of chromatin," said Cowles, who noted that "30 percent of chromatin is regulatory" which can provide an "extra layer of information that we think can be predictive to stratify patients."

EpiCypher has two major business areas: biochemistry, which creates recombinant nucleosomes, and genomic mapping and chromatin profiling technologies. The company's technologies can be used for a number of applications including quantitative mapping of chromatin targets, high-throughput epigenomic profiling of clinical samples, and biochemical characterization of epigenetic targets for drug discovery and inhibitor development.

Watch the video below to learn more.

Machine Bio seeks to fundamentally change how biotechs make protein
Protein purification is one of the biggest bottlenecks for biotechnology companies. However, startup Machine Bio is developing a next-generation protein...

How one CDMO is navigating the global supply chain disruption
The COVID-19 pandemic has disrupted supply chains and production schedules around the world, forcing contract development and manufacturing organizations...

NIH seeks industry partners for technology transfer
The National Institutes of Health (NIH) is the world’s largest public funder of biomedical research. ScienceBoard.net spoke with Michael Salgaller...

A case study on partnering between patient advocacy organizations and biotech
Last week's 2022 Biotechnology Innovation Organization (BIO) International Convention in San Diego gave patient advocacy organizations and biotech companies...

Estonia’s ambitious plans to grow its biotech industry
The Baltic state of Estonia's biotech industry is expected to grow tenfold this decade and offers significant opportunities for Estonian companies. ScienceBoard.net...

Using the power of plants to develop novel biopharmaceuticals
Biologics manufacturing company iBio is using plants as bioreactors to develop and manufacture therapeutics and vaccines. ScienceBoard.net spoke...

Fauna Bio leverages animal genomics, hibernation biology to target human diseases
Biotech company Fauna Bio is leveraging animal genomics and hibernation biology to develop novel translational therapeutics for disease prevention and...

Overcoming the challenges of off-the-shelf allogeneic cell therapies
Chimeric antigen receptor T-cell therapy has emerged as one of the major breakthroughs in cancer immunotherapy in the last decade. In a video interview...

Apeiron Biologics' spinout invIOs targets solid tumors with novel cell therapy platform
Apeiron Biologics' spinout invIOs has a proprietary cell therapy platform for the modulation of intracellular immuno-oncology targets that enables rapid...

Struggle to include women in clinical trials continues despite gains
Though female participation in clinical trials has been steadily improving over the years, most of the women enrolled in trials are white and not members...

Patient advocacy organizations look to partner with pharma companies
Patient advocacy organizations are looking to partner with pharmaceutical companies, offering resources and expertise to maximize the impact and efficiency...

How to develop a sustainable portfolio for cell, gene therapy platforms
Michael Retterath, a Biotechnology Innovation Organization International Convention 2022 panelist and chief business officer at Spark Therapeutics, spoke...

Biotech industry execs, not scientists, remain male-dominated
A panel at the 2022 Biotechnology Innovation Organization International Convention will explore how to close the gender gap in the biotech industry and...

The ‘voice of the patient’ needs to be heard in clinical trials: study
Patient recruitment and retention are among the biggest challenges facing clinical research, particularly in studies targeting rare diseases that have...

New era of nonviral DNA-delivered gene therapy seen emerging
Advancements in nucleic acid-encoded therapeutics over the past decade have sparked the emergence of a new era in nonviral DNA-delivered gene therapy,...

Biotech innovator recounts decades-long journey to create drug discovery technology
Dr. Stan Crooke, PhD, founder, chairman, and chief executive officer of RNA therapy company Ionis Pharmaceuticals, pioneered development of the antisense...